Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®. A Multi-centre, Prospective, Observational, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Effectiveness of Esperoct® in Haemophilia A Patients Under Routine Clinical Practice Conditions in Japan

The purpose of this study is to assess the safety and effectiveness of Esperoct® for long-term routine use in patients with Haemophilia A. Participants will get Esperoct® as prescribed by their doctor. The study will last for about 2 years for each participant.

Inclusion Criteria:

• Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
• Diagnosis of haemophilia A in males or females, no age limitation.
• New patients who have not previously been exposed to Esperoct®.

Exclusion Criteria:

• Previous participation in this study. Participation is defined as having given informed consent in this study.
• Known or suspected hypersensitivity to study product or related products.
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.